Quick Answer
Sigyn Therapeutics, Inc. reported Total Revenue of $143.3 thousand for fiscal year 2019.
Sigyn Therapeutics, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | $143.3K +405.6% |
| Net Income | -$3.34M +19.4% |
-$4.15M -41.5% |
-$2.93M +2.5% |
-$3.00M -138.5% |
-$1.26M +59.0% |
-$3.07M -17.3% |
| Diluted EPS | -$2.51 +33.4% |
-$3.77 -20.4% |
-$3.13 | — | — | — |
| Total Assets | $213.7K -33.6% |
$321.8K -3.3% |
$332.9K -53.1% |
$710.3K +2.3% |
$694.1K | $0.00 -100.0% |
| Cash and Equivalents | $12.1K +3.9% |
$11.7K +39.9% |
$8.4K -97.5% |
$341.0K +304.0% |
$84.4K +16780.4% |
$500.00 -93.3% |
| Stockholders Equity | -$4.46M -30.6% |
-$3.41M -79.3% |
-$1.90M -619.3% |
-$264.6K -366.8% |
$99.2K +10998.8% |
-$910.00 +100.0% |
| R&D Expense | $773.3K -3.1% |
$798.2K +21.4% |
$657.7K -10.4% |
$734.0K +75.0% |
$419.4K | — |
| Operating Income | -$2.52M -2.6% |
-$2.46M -14.3% |
-$2.15M -6.9% |
-$2.01M -119.1% |
-$916.4K -76.9% |
-$518.0K +48.4% |
| Gross Profit | — | — | — | — | — | $107.7K +477.7% |
| Shares Outstanding | 1.61M -96.2% |
42.71M +4365.1% |
956,595 -97.4% |
37.30M +5.9% |
35.20M +6940.3% |
500,000 -99.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2020 | $3.8K | -88.1% | +407.1% |
| Net Income | September 30, 2025 | -$578.5K | +51.7% | +60.1% |
| Diluted EPS | September 30, 2025 | -$0.36 | +61.7% | +60.0% |
| Total Assets | September 30, 2025 | $135.6K | -68.3% | +161.9% |
| Cash and Equivalents | September 30, 2025 | $85.6K | -48.1% | +18542.9% |
| Stockholders Equity | September 30, 2025 | -$5.92M | -50.8% | -8.8% |
| R&D Expense | September 30, 2025 | $29.7K | -85.6% | +296.7% |
| Operating Income | September 30, 2025 | -$386.5K | +52.2% | +17.7% |
| Gross Profit | September 30, 2020 | $2.0K | -91.6% | +312.8% |
| Shares Outstanding | September 30, 2025 | 1.61M | +13.0% | +0.0% |
- Sigyn Therapeutics, Inc. reported Total Revenue of $143.3 thousand for fiscal year 2019.
- Sigyn Therapeutics, Inc. showed an increase of +405.6% in Total Revenue compared to the prior fiscal year.
- Sigyn Therapeutics, Inc. reported Net Income of -$3.34 million for fiscal year 2024.
- Sigyn Therapeutics, Inc. showed an increase of +19.4% in Net Income compared to the prior fiscal year.
- Sigyn Therapeutics, Inc. reported Diluted EPS of $2.51 per share (loss) for fiscal year 2024.
- Sigyn Therapeutics, Inc. showed an increase of +33.4% in Diluted EPS compared to the prior fiscal year.
- Sigyn Therapeutics, Inc. reported Total Assets of $213.7 thousand for fiscal year 2024.
- Sigyn Therapeutics, Inc. showed a decrease of -33.6% in Total Assets compared to the prior fiscal year.
- Sigyn Therapeutics, Inc. reported Cash and Equivalents of $12.1 thousand for fiscal year 2024.
- Sigyn Therapeutics, Inc. showed an increase of +3.9% in Cash and Equivalents compared to the prior fiscal year.
- Sigyn Therapeutics, Inc. reported Stockholders Equity of -$4.46 million for fiscal year 2024.
- Sigyn Therapeutics, Inc. showed a decrease of -30.6% in Stockholders Equity compared to the prior fiscal year.
- Sigyn Therapeutics, Inc. reported R&D Expense of $773.3 thousand for fiscal year 2024.
- Sigyn Therapeutics, Inc. showed a decrease of -3.1% in R&D Expense compared to the prior fiscal year.
- Sigyn Therapeutics, Inc. reported Operating Income of -$2.52 million for fiscal year 2024.
- Sigyn Therapeutics, Inc. showed a decrease of -2.6% in Operating Income compared to the prior fiscal year.
- Sigyn Therapeutics, Inc. reported Gross Profit of $107.7 thousand for fiscal year 2019.
- Sigyn Therapeutics, Inc. showed an increase of +477.7% in Gross Profit compared to the prior fiscal year.
- Sigyn Therapeutics, Inc. reported Shares Outstanding of 1.61 million shares for fiscal year 2024.
- Sigyn Therapeutics, Inc. showed an increase of +24.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: